SELDI-TOF-based TTP diagnostic test, which already has been
commercially launched as a laboratory developed test by the
institution, also could be used to help estimate the risk of TTP
relapses during clinical remission. The data -- published in the
online edition of the British Journal of Haematology -- indicate
that use of the test may provide a novel screening strategy to
identify patients who may benefit from prophylactic treatment to
help prevent relapse of this serious blood disorder.
-- Corporate Developments
* Appointed John F. Hamilton, former vice president and chief
financial officer of Depomed, Inc., to the Vermillion Board of
Directors and to serve as chairman of the Audit Committee of the
* Received issuance of U.S. Patent No. 7,341,838 for the discovery of
novel forms of brain natriuretic peptide (BNP), which could
potentially improve upon the current standard of care in diagnosing
and treating cardiovascular disease. The discovery could ultimately
lead to the development of an improved, next-generation assay that
might provide physicians with additional, valuable information to
stratify patients at risk for cardiovascular disease.
* Renewed a long-standing collaboration with Johns Hopkins University
on the development of novel biomarkers that can be applied toward
disease detection, classification and monitoring of prevalent
cancers, including ovarian, breast and prostate. Vermillion will
have access to exclusive commercial rights to the discoveries made
through the partnership.
* Vermillion's stockholders and board of directors approved a 1 for
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved